Becton, Dickinson and Company
Becton, Dickinson and Company BDXB Peers
See (BDXB) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.40% |
| ISRG | $533.71 | -0.09% | 191.3B | 78.14 | $6.83 | N/A |
| BDX | $170.84 | +0.51% | 49B | 33.11 | $5.16 | +2.40% |
| BDXA | $59.24 | -2.24% | 48.7B | 21.44 | $2.76 | +2.40% |
| ALC | $87.81 | +0.80% | 43.4B | 39.03 | $2.25 | +0.38% |
| RMD | $254.99 | -0.48% | 37.4B | 28.62 | $8.91 | +0.83% |
| WST | $219.02 | +0.01% | 15.7B | 34.44 | $6.36 | +0.38% |
| BAX | $30.39 | -0.36% | 15.6B | -58.44 | -$0.52 | +2.63% |
| HOLX | $65.01 | -0.15% | 14.5B | 27.32 | $2.38 | N/A |
| COO | $71.14 | +2.08% | 14.2B | 34.37 | $2.07 | N/A |
Stock Comparison
BDXB vs ISRG Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ISRG has a market cap of 191.3B. Regarding current trading prices, BDXB is priced at $48.16, while ISRG trades at $533.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ISRG's P/E ratio is 78.14. In terms of profitability, BDXB's ROE is +0.06%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, BDXB is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs BDX Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BDX has a market cap of 49B. Regarding current trading prices, BDXB is priced at $48.16, while BDX trades at $170.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BDX's P/E ratio is 33.11. In terms of profitability, BDXB's ROE is +0.06%, compared to BDX's ROE of +0.06%. Regarding short-term risk, BDXB is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs BDXA Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BDXA has a market cap of 48.7B. Regarding current trading prices, BDXB is priced at $48.16, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BDXA's P/E ratio is 21.44. In terms of profitability, BDXB's ROE is +0.06%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, BDXB is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs ALC Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ALC has a market cap of 43.4B. Regarding current trading prices, BDXB is priced at $48.16, while ALC trades at $87.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ALC's P/E ratio is 39.03. In terms of profitability, BDXB's ROE is +0.06%, compared to ALC's ROE of +0.07%. Regarding short-term risk, BDXB is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs RMD Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, RMD has a market cap of 37.4B. Regarding current trading prices, BDXB is priced at $48.16, while RMD trades at $254.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas RMD's P/E ratio is 28.62. In terms of profitability, BDXB's ROE is +0.06%, compared to RMD's ROE of +0.25%. Regarding short-term risk, BDXB is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs WST Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, WST has a market cap of 15.7B. Regarding current trading prices, BDXB is priced at $48.16, while WST trades at $219.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas WST's P/E ratio is 34.44. In terms of profitability, BDXB's ROE is +0.06%, compared to WST's ROE of +0.17%. Regarding short-term risk, BDXB is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs BAX Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BAX has a market cap of 15.6B. Regarding current trading prices, BDXB is priced at $48.16, while BAX trades at $30.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BAX's P/E ratio is -58.44. In terms of profitability, BDXB's ROE is +0.06%, compared to BAX's ROE of -0.08%. Regarding short-term risk, BDXB is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs HOLX Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HOLX has a market cap of 14.5B. Regarding current trading prices, BDXB is priced at $48.16, while HOLX trades at $65.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HOLX's P/E ratio is 27.32. In terms of profitability, BDXB's ROE is +0.06%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDXB is less volatile compared to HOLX. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs COO Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, COO has a market cap of 14.2B. Regarding current trading prices, BDXB is priced at $48.16, while COO trades at $71.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas COO's P/E ratio is 34.37. In terms of profitability, BDXB's ROE is +0.06%, compared to COO's ROE of +0.05%. Regarding short-term risk, BDXB is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs ATR Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATR has a market cap of 10.3B. Regarding current trading prices, BDXB is priced at $48.16, while ATR trades at $155.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATR's P/E ratio is 28.49. In terms of profitability, BDXB's ROE is +0.06%, compared to ATR's ROE of +0.15%. Regarding short-term risk, BDXB is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs MASI Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MASI has a market cap of 9.1B. Regarding current trading prices, BDXB is priced at $48.16, while MASI trades at $168.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MASI's P/E ratio is -30.75. In terms of profitability, BDXB's ROE is +0.06%, compared to MASI's ROE of -0.41%. Regarding short-term risk, BDXB is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs RGEN Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, RGEN has a market cap of 6.9B. Regarding current trading prices, BDXB is priced at $48.16, while RGEN trades at $123.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas RGEN's P/E ratio is -294.19. In terms of profitability, BDXB's ROE is +0.06%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, BDXB is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs STVN Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, STVN has a market cap of 6.7B. Regarding current trading prices, BDXB is priced at $48.16, while STVN trades at $24.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas STVN's P/E ratio is 46.53. In terms of profitability, BDXB's ROE is +0.06%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BDXB is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs MMSI Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MMSI has a market cap of 5.5B. Regarding current trading prices, BDXB is priced at $48.16, while MMSI trades at $93.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MMSI's P/E ratio is 45.83. In terms of profitability, BDXB's ROE is +0.06%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDXB is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs TFX Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, TFX has a market cap of 5.3B. Regarding current trading prices, BDXB is priced at $48.16, while TFX trades at $119.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas TFX's P/E ratio is 36.94. In terms of profitability, BDXB's ROE is +0.06%, compared to TFX's ROE of +0.03%. Regarding short-term risk, BDXB is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs BLCO Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BLCO has a market cap of 4.4B. Regarding current trading prices, BDXB is priced at $48.16, while BLCO trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BLCO's P/E ratio is -12.17. In terms of profitability, BDXB's ROE is +0.06%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, BDXB is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs HAE Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HAE has a market cap of 3.5B. Regarding current trading prices, BDXB is priced at $48.16, while HAE trades at $73.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HAE's P/E ratio is 22.29. In terms of profitability, BDXB's ROE is +0.06%, compared to HAE's ROE of +0.18%. Regarding short-term risk, BDXB is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs ICUI Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ICUI has a market cap of 3.2B. Regarding current trading prices, BDXB is priced at $48.16, while ICUI trades at $131.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ICUI's P/E ratio is -34.42. In terms of profitability, BDXB's ROE is +0.06%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, BDXB is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs XRAY Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, XRAY has a market cap of 3.2B. Regarding current trading prices, BDXB is priced at $48.16, while XRAY trades at $15.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas XRAY's P/E ratio is -3.56. In terms of profitability, BDXB's ROE is +0.06%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, BDXB is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs WRBY Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, WRBY has a market cap of 2.7B. Regarding current trading prices, BDXB is priced at $48.16, while WRBY trades at $21.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas WRBY's P/E ratio is -182.42. In terms of profitability, BDXB's ROE is +0.06%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, BDXB is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs NVCR Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, BDXB is priced at $48.16, while NVCR trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NVCR's P/E ratio is -11.92. In terms of profitability, BDXB's ROE is +0.06%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, BDXB is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs QDEL Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, QDEL has a market cap of 2B. Regarding current trading prices, BDXB is priced at $48.16, while QDEL trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas QDEL's P/E ratio is -5.52. In terms of profitability, BDXB's ROE is +0.06%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, BDXB is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs LMAT Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, BDXB is priced at $48.16, while LMAT trades at $82.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas LMAT's P/E ratio is 41.91. In terms of profitability, BDXB's ROE is +0.06%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, BDXB is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs ATRC Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, BDXB is priced at $48.16, while ATRC trades at $32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATRC's P/E ratio is -39.85. In terms of profitability, BDXB's ROE is +0.06%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, BDXB is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs AZTA Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, AZTA has a market cap of 1.4B. Regarding current trading prices, BDXB is priced at $48.16, while AZTA trades at $30.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas AZTA's P/E ratio is -9.35. In terms of profitability, BDXB's ROE is +0.06%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, BDXB is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs NNNN Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NNNN has a market cap of 1.4B. Regarding current trading prices, BDXB is priced at $48.16, while NNNN trades at $31.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NNNN's P/E ratio is 624.20. In terms of profitability, BDXB's ROE is +0.06%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, BDXB is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs BLFS Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BLFS has a market cap of 1B. Regarding current trading prices, BDXB is priced at $48.16, while BLFS trades at $21.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BLFS's P/E ratio is -113.11. In terms of profitability, BDXB's ROE is +0.06%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BDXB is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs PLSE Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, PLSE has a market cap of 1B. Regarding current trading prices, BDXB is priced at $48.16, while PLSE trades at $15.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas PLSE's P/E ratio is -15.23. In terms of profitability, BDXB's ROE is +0.06%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, BDXB is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs KMTS Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, KMTS has a market cap of 907.3M. Regarding current trading prices, BDXB is priced at $48.16, while KMTS trades at $17.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas KMTS's P/E ratio is -9.20. In terms of profitability, BDXB's ROE is +0.06%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, BDXB is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs STAA Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, STAA has a market cap of 838M. Regarding current trading prices, BDXB is priced at $48.16, while STAA trades at $16.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas STAA's P/E ratio is -11.75. In terms of profitability, BDXB's ROE is +0.06%, compared to STAA's ROE of -0.18%. Regarding short-term risk, BDXB is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs ATRI Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDXB is priced at $48.16, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDXB's ROE is +0.06%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, BDXB is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs ANGO Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ANGO has a market cap of 397.1M. Regarding current trading prices, BDXB is priced at $48.16, while ANGO trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ANGO's P/E ratio is -9.68. In terms of profitability, BDXB's ROE is +0.06%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDXB is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs NYXH Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NYXH has a market cap of 280M. Regarding current trading prices, BDXB is priced at $48.16, while NYXH trades at $7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NYXH's P/E ratio is -3.25. In terms of profitability, BDXB's ROE is +0.06%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, BDXB is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs SMTI Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, SMTI has a market cap of 252.5M. Regarding current trading prices, BDXB is priced at $48.16, while SMTI trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas SMTI's P/E ratio is -21.20. In terms of profitability, BDXB's ROE is +0.06%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, BDXB is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs OSUR Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, OSUR has a market cap of 225.1M. Regarding current trading prices, BDXB is priced at $48.16, while OSUR trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas OSUR's P/E ratio is -7.17. In terms of profitability, BDXB's ROE is +0.06%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, BDXB is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs STXS Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, STXS has a market cap of 195.2M. Regarding current trading prices, BDXB is priced at $48.16, while STXS trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas STXS's P/E ratio is -7.32. In terms of profitability, BDXB's ROE is +0.06%, compared to STXS's ROE of -2.17%. Regarding short-term risk, BDXB is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs UTMD Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, UTMD has a market cap of 187.7M. Regarding current trading prices, BDXB is priced at $48.16, while UTMD trades at $57.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas UTMD's P/E ratio is 15.25. In terms of profitability, BDXB's ROE is +0.06%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, BDXB is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs KRMD Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, KRMD has a market cap of 167.5M. Regarding current trading prices, BDXB is priced at $48.16, while KRMD trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas KRMD's P/E ratio is -30.25. In terms of profitability, BDXB's ROE is +0.06%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, BDXB is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs PDEX Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, PDEX has a market cap of 146.4M. Regarding current trading prices, BDXB is priced at $48.16, while PDEX trades at $44.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas PDEX's P/E ratio is 16.26. In terms of profitability, BDXB's ROE is +0.06%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDXB is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs INFU Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, INFU has a market cap of 131.1M. Regarding current trading prices, BDXB is priced at $48.16, while INFU trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas INFU's P/E ratio is 41.67. In terms of profitability, BDXB's ROE is +0.06%, compared to INFU's ROE of +0.08%. Regarding short-term risk, BDXB is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs ZTEK Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ZTEK has a market cap of 118.9M. Regarding current trading prices, BDXB is priced at $48.16, while ZTEK trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ZTEK's P/E ratio is -14.25. In terms of profitability, BDXB's ROE is +0.06%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, BDXB is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs ZJYL Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ZJYL has a market cap of 101.7M. Regarding current trading prices, BDXB is priced at $48.16, while ZJYL trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ZJYL's P/E ratio is 32.49. In terms of profitability, BDXB's ROE is +0.06%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, BDXB is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs MBOT Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MBOT has a market cap of 90.5M. Regarding current trading prices, BDXB is priced at $48.16, while MBOT trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MBOT's P/E ratio is -3.89. In terms of profitability, BDXB's ROE is +0.06%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, BDXB is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs AKYA Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, AKYA has a market cap of 61.9M. Regarding current trading prices, BDXB is priced at $48.16, while AKYA trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas AKYA's P/E ratio is -1.29. In terms of profitability, BDXB's ROE is +0.06%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, BDXB is less volatile compared to AKYA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs MLSS Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MLSS has a market cap of 55.3M. Regarding current trading prices, BDXB is priced at $48.16, while MLSS trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MLSS's P/E ratio is -11.73. In terms of profitability, BDXB's ROE is +0.06%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, BDXB is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs OMIC Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDXB is priced at $48.16, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDXB's ROE is +0.06%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, BDXB is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs IGAP Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDXB is priced at $48.16, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDXB's ROE is +0.06%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, BDXB is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs DXR Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, DXR has a market cap of 45.4M. Regarding current trading prices, BDXB is priced at $48.16, while DXR trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas DXR's P/E ratio is -101.67. In terms of profitability, BDXB's ROE is +0.06%, compared to DXR's ROE of +0.02%. Regarding short-term risk, BDXB is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs NEPH Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NEPH has a market cap of 40.7M. Regarding current trading prices, BDXB is priced at $48.16, while NEPH trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NEPH's P/E ratio is 48.00. In terms of profitability, BDXB's ROE is +0.06%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, BDXB is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs POCI Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, POCI has a market cap of 37.7M. Regarding current trading prices, BDXB is priced at $48.16, while POCI trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas POCI's P/E ratio is -5.41. In terms of profitability, BDXB's ROE is +0.06%, compared to POCI's ROE of -0.54%. Regarding short-term risk, BDXB is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs SDC Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDXB is priced at $48.16, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDXB's ROE is +0.06%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDXB is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs FEMY Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, FEMY has a market cap of 28.6M. Regarding current trading prices, BDXB is priced at $48.16, while FEMY trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas FEMY's P/E ratio is -1.08. In terms of profitability, BDXB's ROE is +0.06%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, BDXB is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs IVC Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDXB is priced at $48.16, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDXB's ROE is +0.06%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDXB is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs HBIO Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HBIO has a market cap of 20.5M. Regarding current trading prices, BDXB is priced at $48.16, while HBIO trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HBIO's P/E ratio is -0.35. In terms of profitability, BDXB's ROE is +0.06%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, BDXB is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs RVP Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, RVP has a market cap of 19.8M. Regarding current trading prices, BDXB is priced at $48.16, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas RVP's P/E ratio is -0.87. In terms of profitability, BDXB's ROE is +0.06%, compared to RVP's ROE of -0.27%. Regarding short-term risk, BDXB is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs NXGL Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NXGL has a market cap of 18.4M. Regarding current trading prices, BDXB is priced at $48.16, while NXGL trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NXGL's P/E ratio is -5.33. In terms of profitability, BDXB's ROE is +0.06%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, BDXB is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs WOK Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, WOK has a market cap of 17.8M. Regarding current trading prices, BDXB is priced at $48.16, while WOK trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas WOK's P/E ratio is -2.65. In terms of profitability, BDXB's ROE is +0.06%, compared to WOK's ROE of -0.30%. Regarding short-term risk, BDXB is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs NXGLW Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NXGLW has a market cap of 17.1M. Regarding current trading prices, BDXB is priced at $48.16, while NXGLW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NXGLW's P/E ratio is -0.19. In terms of profitability, BDXB's ROE is +0.06%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, BDXB is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs MHUA Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MHUA has a market cap of 14.3M. Regarding current trading prices, BDXB is priced at $48.16, while MHUA trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MHUA's P/E ratio is 1.13. In terms of profitability, BDXB's ROE is +0.06%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, BDXB is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs LUCYW Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, LUCYW has a market cap of 13.8M. Regarding current trading prices, BDXB is priced at $48.16, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BDXB's ROE is +0.06%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, BDXB is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs EKSO Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, EKSO has a market cap of 8M. Regarding current trading prices, BDXB is priced at $48.16, while EKSO trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas EKSO's P/E ratio is -0.47. In terms of profitability, BDXB's ROE is +0.06%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, BDXB is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs POAI Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, POAI has a market cap of 7.4M. Regarding current trading prices, BDXB is priced at $48.16, while POAI trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas POAI's P/E ratio is -0.58. In terms of profitability, BDXB's ROE is +0.06%, compared to POAI's ROE of -5.91%. Regarding short-term risk, BDXB is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs LUCY Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, LUCY has a market cap of 6.4M. Regarding current trading prices, BDXB is priced at $48.16, while LUCY trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas LUCY's P/E ratio is 0.05. In terms of profitability, BDXB's ROE is +0.06%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, BDXB is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs STSS Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, STSS has a market cap of 5.6M. Regarding current trading prices, BDXB is priced at $48.16, while STSS trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas STSS's P/E ratio is N/A. In terms of profitability, BDXB's ROE is +0.06%, compared to STSS's ROE of -0.99%. Regarding short-term risk, BDXB is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs NSTG Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDXB is priced at $48.16, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDXB's ROE is +0.06%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDXB is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs GCTK Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, GCTK has a market cap of 3.7M. Regarding current trading prices, BDXB is priced at $48.16, while GCTK trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas GCTK's P/E ratio is N/A. In terms of profitability, BDXB's ROE is +0.06%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, BDXB is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs GMVD Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDXB is priced at $48.16, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDXB's ROE is +0.06%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDXB is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs GMVDW Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDXB is priced at $48.16, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDXB's ROE is +0.06%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDXB is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs AVGR Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDXB is priced at $48.16, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDXB's ROE is +0.06%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, BDXB is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for BDXB.
BDXB vs IIN Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDXB's ROE is +0.06%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDXB is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs HRC Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDXB's ROE is +0.06%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDXB is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs LMNX Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, LMNX has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas LMNX's P/E ratio is N/A. In terms of profitability, BDXB's ROE is +0.06%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, BDXB is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs ATRS Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDXB's ROE is +0.06%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDXB is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.
BDXB vs APR Comparison
BDXB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas APR's P/E ratio is 22.59. In terms of profitability, BDXB's ROE is +0.06%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDXB is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXB.